A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2
Related Posts
Martínez E, Watanabe M, Hoffman R, Zanni MV, Pozniak A, Shakil SS, McCallum S, Chu SM, Srinivasa S, Malvestutto CD, Fichtenbaum CJ, Bloomfield GS, Sponseller[...]
Sherwood K, Zhang N, David H, Dekker A, Garner O, Samuels E, Adamson P. Missed Opportunities for HIV and Syphilis Co-Testing in Emergency Departments. Clin[...]
Chan LC, Lee HK, Wang L, Wang H, Filler SG, Ciranna A, Abdelhady W, Xiong YQ, Li L, Gonzales RA, Ruffin F, Fowler VG Jr,[...]